Liplasome raises investment for testing a novel drug delivery technology  

2005.04.19
Danish biotech company Liplasome has gained a DKK 45 mn investment for testing its novel tumour activated drug delivery technology for the treatment of cancer

Danish biotech company Liplasome has gained a DKK 45 mn (USD 7.6 mn) investment from investors including BankInvest, Vecata and Incuba Venture. Liplasome is developing a novel targeted and tumour activated drug delivery technology for the treatment of cancer. Clinical tests in mice have shown that Liplasome's drug reduces tumours significantly; the money will be used to bring the cancer drug into the first stage of clinical testing in humans.

The new tumour activated delivery platform allows intravenous transport of high concentrations of encapsulated anticancer drugs such as anthracyclines to cancer tissue. Degradation of the drug loaded nanocarriers by cancer enzymes leads to release and activation of the drugs specifically at the location of the target tumour.

Torben Vilsgaard from Incuba Venture says, "Liplasome Pharma's delivery platform is particularly useful for tumour specific transport of chemotherapeutics, which are often extremely toxic towards both cancerous and healthy tissue". The news is reported by professional journal Ingeniøren (the Engineer) and on Liplasome's website.

Liplasome which was founded in 2001, is based at the Chemical Institute at the Technical University of Denmark. Including the new investment, the company has received DKK 65 mn (USD 11 mn) in funding.

Link > Liplasome 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×